Skip to main content
Theresa Podrebarac, MD, Rheumatology, Cambridge, MA

Theresa Anne Podrebarac MD


Physician

Join to View Full Profile
  • 245 1st StSte 16Cambridge, MA 02142

  • Phone+1 617-301-7076

  • Fax+1 617-301-7030

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 3 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Theresa Podrebarac, MD is a rheumatologist in Cambridge, Massachusetts. She is currently licensed to practice medicine in Massachusetts.

Education & Training

  • University of Western Ontario
    University of Western OntarioClass of 1990

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1996 - 2015

Awards, Honors, & Recognition

  • Fellow (FACR) American College of Rheumatology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Horizon Therapeutics Plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
    Horizon Therapeutics Plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus ErythematosusJanuary 4th, 2023
  • Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (Pegloticase Injection) plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA Monotherapy
    Data Presented from the MIRROR Randomized Controlled Trial Demonstrate KRYSTEXXA® (Pegloticase Injection) plus Methotrexate Resulted in Significant Improvement in Efficacy and Safety (Infusion Reactions) Compared to KRYSTEXXA MonotherapyJune 1st, 2022
  • First IPF Patient Enrolled in Phase 2b Trial of Oral HZN-825
    First IPF Patient Enrolled in Phase 2b Trial of Oral HZN-825January 25th, 2022
  • Join now to see all

Professional Memberships